Robotic medical crash cart eases workload for health care teams

Health care workers have an intense workload and often experience mental distress during resuscitation and other critical care procedures. Although researchers have studied whether robots can support human teams in other high-stakes, high-risk settings such as disaster response and military operations, the role of robots in emergency medicine has not been explored.

Enter Angelique Taylor, the Andrew H. and Ann R. Tisch Assistant Professor at Cornell Tech and the Cornell Ann S. Bowers College of Computing and Information Science. She is also an assistant professor in emergency medicine at Weill Cornell Medicine and director of the Artificial Intelligence and Robotics Lab (AIRLab) at Cornell Tech.

In a pair of articles published at the Institute of Electrical and Electronics Engineers (IEEE) conference on Robot and Human Interactive Communication (RO-MAN) in August 2025, Taylor and her collaborators at Weill Cornell Medicine, associate professor Kevin Ching and assistant professor Jonathan St. George, described research on their new robotic crash cart (RCC)—a robotic version of the mobile drawer unit that holds supplies and equipment needed for a range of medical procedures.

“Health care workers may not know or may forget where all the various supplies are located in the cart drawers, and often they’re kind of shuffling through the cart,” Taylor said. This can cause delays during emergency procedures that require iterative tasks with precise timing, exacerbating medical errors and putting patients at risk, she noted.

To create the RCC, Taylor and her team outfitted a standard cart with LED light strips, a speaker, and a touchscreen tablet integrated with the Robot Operating System. This middleware connects computer programs to robot hardware, enabling them to work together to provide users with verbal and nonverbal cues.

During an emergency procedure, a user can request the location of a supply on the tablet. Then the lights around the drawer with that supply blink, or a spoken instruction plays through the speaker. Users can also receive prompts to remind them about necessary medications and recommend supplies.

In their article, “Help or Hindrance: Understanding the Impact of Robot Communication in Action Teams,” Taylor’s team conducted pilot studies of the RCC. One pilot involved 84 participants, aged 21 to 79, about half of whom had a clinical background. Working in groups of 3 to 4, they conducted a series of simulated resuscitation procedures with a manikin patient using three different carts: a RCC with blinking lights for object search and spoken task reminders, a RCC with blinking lights for task reminders and spoken language for object search, or a standard cart.

The team found that participants preferred the RCC that provided verbal and nonverbal cues over no cues with the standard cart—rating it lower in terms of workload and higher in usefulness and ease of use.

“These results were exciting and achieved statistical significance, suggesting that the use of a robot is beneficial,” said Taylor. The article, by Taylor, Ph.D. student Tauhid Tanjim, and colleagues at Weill Cornell, was a Kazuo-Tanie Paper Award finalist, an honor given to the top three papers in their category at the conference.

In the second article, “Human-Robot Teaming Field Deployments: A Comparison Between Verbal and Non-verbal Communication,” the research team began testing the RCC under more realistic conditions. Participants were health care workers from across the United States, and actors played frantic family members during the simulations.

Similar to the pilot studies, Taylor, along with colleagues at Cornell and Michigan State University, found that the RCC reduced participant workload, depending on whether the robot provided verbal or non-verbal cues. However, they evaluated robots with only one type of cue, not both, and identified room for improvement, particularly in the robot’s visual cues. They are now studying health care workers’ impressions of an RCC with multimodal communication.

Taylor hopes that other research teams will start exploring how robots can support health care teams in critical care settings. To that end, Taylor and her colleague presented an article at the February 2025 Association for Computing Machinery/IEEE International Conference that offers a toolkit for researchers to build their own RCC.

The papers are all published on the arXiv pre-print server.

Specific brain signals rapidly eliminate body fat in mice

Researchers at WashU Medicine have identified a potent pathway that begins in the brain and leads to loss of all body fat without reducing food intake. The study is reported in Nature Metabolism.

The team—led by senior author Erica L. Scheller, DDS, Ph.D., an associate professor in the Division of Bone and Mineral Diseases in the Department of Medicine; Xiao Zhang, Ph.D., a former graduate student in Scheller’s lab who is now a postdoctoral fellow at the University of Pennsylvania School of Medicine; and Sree Panicker, a graduate student in Scheller’s lab—was inspired by a unique population of fat cells located deep within the skeleton.

“About 70% of our bone marrow is filled with fat that doesn’t respond to diet or exercise,” said senior author Scheller. “We wanted to figure out why.”

The team found that these special cells, called constitutive bone marrow adipocytes, expressed high levels of proteins that inhibit fat breakdown. This causes resistance to fat loss in day-to-day settings. “We call these cells stable adipocytes,” said Zhang, the study’s first author. In mice, sustained injection of leptin, a hormone, into the brain was able to unlock the stable adipocytes by putting the body into a state of low glucose and insulin. This reduced the inhibitors of fat breakdown, causing complete loss of body fat within days, even though the mice were still eating normally.

This pathway is so powerful that scientists caution against using it in humans until it is better understood. Stable adipocytes occur in places like the bone marrow, in the hands and feet, and around important glands. In severe wasting disorders, loss of fat within these cells is associated with bone fractures and reduced quality of life.

Scheller’s team hopes to prevent this loss and preserve health in patients with severe wasting disorders by defining the mechanisms of stable fat loss. Conversely, methods to activate fat loss from stubborn adipocytes may support future treatments for obesity.

Modulated UV-C light increases the shelf life of guavas, study shows

The application of modulated UV-C light to guavas—emitted in pulses or cycles rather than continuously—combated anthracnose. This fungal disease is caused by microorganisms belonging to the Colletotrichum gloeosporioides complex and triggers dark lesions on the fruit after harvest, reducing its shelf life. An article on the technique was published in the journal Horticulturae.

The disease usually manifests on the skin but can reach the pulp through injuries caused by insects, improper handling, or mechanical damage during transport. These factors, combined with inefficient post-harvest practices, contribute to an estimated 20% to 40% loss of total guava production in developing countries.

In this type of food, pathogen control has predominantly been carried out through the use of synthetic chemical pesticides, particularly fungicides. This involves immersing or spraying the fruit in a fungicide solution immediately after harvest, followed by drying and refrigerated storage.

“The chemicals used in post-harvest treatment end up causing chemical contamination, which is very harmful to human health, especially children, and to the environment. So, in this study … our goal was not only to provide an effective method of controlling this disease post-harvest, but also to develop a clean and sustainable technology that would leave no residue and preserve the integrity of the food,” says Daniel Terao, an agronomist and researcher at the Brazilian Agricultural Research Corporation (EMBRAPA) who participated in the study.

The new treatment developed by EMBRAPA consists of a cylindrical device with a mirror and three internal UV-C germicidal lamps. One lamp emits rays of light perpendicular to the surface of the structure, creating a cylinder of light. The second lamp is strategically positioned toward the mirror to reflect on the guava. The third lamp faces the fruit directly.

This mechanism ensures the food is illuminated by the maximum amount of radiation, which is absorbed on the surface and converted into heat. This inactivates microorganisms.

“This allows for more precise control of the product’s interaction with the light and reduces light energy losses, controlling the fungus that causes the disease and minimizing damage to the food’s epidermis. In this way, natural resistance mechanisms are enhanced, which means that the fruit itself is activated against the attack of microorganisms, preserving the quality of the food and increasing its shelf life,” Terao explains.

According to the researcher, the results of the study were very promising for treating guavas and other fruits, but they only occurred in a laboratory environment.

The next step is to validate the technology under real conditions at the producer’s facility and adapt the modulated UV-C light application equipment to the fruit processing line. This will allow the technique to be applied in practice.

Silent witnesses: Pets offer a fur-ensic tale

New research confirms the potential for police forensic investigators to carefully consider the presence of pets at crime scenes as a credible new avenue for finding and investigating DNA leads to solve the case. The Long-running research by Flinders University and Victoria Police experts demonstrates how dogs and cats can be tested for indirect DNA transfer at crime scenes from people other than householders or pet owners.

Heidi Monkman, Ph.D. student from Flinders University’s College of Science and Engineering, with Dr. Roland van Oorschot from the Victoria Police Forensic Services Department and Luke Volgin from the Forensic Science South Australia, are breaking new ground with their research on animal-mediated human DNA transfer. Their recent studies reveal that household pets may play a surprising role in solving crimes.

“Dogs and cats are present in the majority of households worldwide and they routinely interact with multiple people and environments. Our findings show that dogs and cats can act as intermediaries in human DNA transfer, which has significant implications for casework where animals are present,” says Dr. Monkman, a co-author of several forensic DNA science articles on the topic.

The research discovered that even short contact between pets and people of interest, including potential offenders, leave detectable traces of human DNA on pets. It also found cats and dogs carry and spread human DNA as they move around a home or to other locations, transferring it from one surface to another.

“Awareness and use of this phenomenon could offer investigators important clues when piecing together evidence in serious criminal cases,” says Monkman.

The studies involved controlled interactions between dogs, cats and volunteers in order to monitor DNA transfer in various scenarios. They found that owners’ DNA present on their pets can be picked up by mock offenders, potentially linking them to crime scenes. The DNA also can be transferred to locations that the owners never touched, possibly linking them to crime scenes where they were not present.

In the most recent article, “Investigation of human DNA transfer during mock dog-napping,” published in Forensic Science International, researchers examined human DNA transfer dynamics in a mock “dog-napping” scenario.

Five dogs were placed into five separate cars by a recruited handler. The vehicles were neither owned by the handler nor familiar to the animals or their owners. The dogs remained in a car for 20 minutes and then returned home, where sampling took place one hour later.

Flinders University Senior Lecturer in Forensic Science Dr. Mariya Goray—a co-author of the journal articles—says while pets have often been overlooked in forensic casework, this research highlights their potential critical role in the dynamics of DNA transfer.

“These findings highlight the need for forensic investigators to carefully consider the presence of pets at crime scenes both as a possible new avenue for investigative leads, but also as a possible mechanism for indirect transfer and contamination,” says Dr. Goray.

In another journal article, “The role of cats in human DNA transfer” in Forensic Science International: Genetics, 20 different cats were tested; quantifiable DNA was detected in 16 or 80% of the samples taken.

The third paper, titled “Paws for a moment: Investigation of bi-directional transfer of human DNA during a short human-dog interaction and subsequent indirect transfer,” is published in Science & Justice.

“While little is known about collecting and analyzing human DNA to and from cats, we are exploring the potential for cats and dogs to be silent witnesses, to act as vectors of contamination and transfer at residential crime scenes,” says Monkman. “We know about 60% of households currently have a pet, and up to 90% a pet at some stage. They are the most common pet in most countries around the world.”

Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial

The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical trial.

Shares of Evommune, a member of the late-2025 biotech IPO class, rose 75% on Tuesday after the therapeutic protein EVO301 eased the severity of atopic dermatitis by 33% in a mid-stage trial.

Those numbers position Evommune to complete with the likes of Regeneron and Sanofi, which market one of the biggest drugs in the world for dermatitis, Dupixent, analysts at William Blair wrote on Tuesday.

Dupixent earned $17.8 billion in 2025, a 26% increase from 2024, according to Regeneron’s full-year 2025 earnings report.

Shares of Evommune climbed 75% to $29.87 in Tuesday morning trading.

In a Phase 2a trial that the company described in a Tuesday release as “proof-of-concept,” Evommune tracked 70 patients for 12 weeks after they were given an intravenous dose of EVO301 on the first day and the 28th day of the trial, both of the same dose level. There were 48 patients in the treatment arm and 22 in the placebo group.

After 12 weeks, patients in the treatment arm saw a 55% reduction in eczema severity versus 22% for patients in the placebo arm, a 33% placebo-adjusted rate.

EVO301’s results are “highly encouraging,” the William Blair analysts said, especially given that Dupixent showed a 35% to 36% placebo-adjusted improvement after 16 weeks in a Phase 3 trial, and that EVO301 was only tested at one dose level. “We believe greater efficacy could be achieved with a more optimized dosing regimen,” the analysts added.

Evommune plans to test just that in a Phase 2b dose-ranging trial using a subcutaneous formulation of EVO301. More data from the Phase 2a trial will be presented at an upcoming medical conference, according to Tuesday’s statement. Evommune is also evaluating the candidate in other indications like ulcerative colitis.

EVO301 is a fusion protein designed to bind IL-18, an inflammatory cytokine implicated in a number of immune conditions, including dermatitis.

In late October 2025, Evommune joined a sudden rush of biotechs attempting IPOs, raising $172.5 million to back its immunology and inflammation pipeline. The biotech’s lead molecule is EVO756, which blocks the MRGPRX2 receptor and is being tested for chronic spontaneous urticaria and atopic dermatitis.

Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter

The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, birds insects, and other vermin.”

In a warning letter issued in June last year to MedisourceRx, a compounding pharmacy owned by Hims & Hers, the FDA cited clear violations of good manufacturing practices. The revelations, first reported Monday by STAT News, add to the troubles of the telehealth company, which has come under fire from both regulators and Novo Nordisk for selling compounded semaglutide.

An FDA inspector found that facilities for drug manufacturing, processing, packaging or storage “are not free of infestation by rodents, birds insects [sic], and other vermin,” according to the warning letter. The inspector also spotted a live spider in the area where MedisourceRx produced active pharmaceutical ingredients for human drugs.

Among these products, the warning letter specified, was Hims & Hers’ compounded semaglutide injection.

The FDA also flagged a dead cricket which “was observed in the middle of the incubator room.” MedisourceRx uses these incubators for fill vials as part of the manufacturing of drugs for human use.

Aside from the infestation, the FDA inspector also noted that one patient who had taken a dose of injectable compounded semaglutide experienced severe gastrointestinal issues that necessitated “three nights of hospital stay.” MedisourceRx “has not submitted an adverse event report” as required, the letter claimed.

“Patient safety and regulatory compliance are foundational to how we operate,” a spokesperson for Hims & Hers told STAT News, which reported that the FDA sent a second letter to MedisourceRx in December 2025, which has yet to be released publicly.

The spokesperson also told STAT that the company is working on addressing the FDA’s concerns about reporting of toxicities, but insisted that the issues of infestation enumerated in the June letter no longer appear in the December communique. The spokesperson did not provide STAT a copy of this latter letter.

The last few days have been rough for Hims. The company last week launched a compounded version of oral semaglutide, triggering a firestorm of backlash from regulatory authorities and Novo Nordisk. FDA Commissioner Marty Makary said in an X post that the agency will “take swift action against companies mass-marketing illegal copycat drugs.”

Mike Stuart, general counsel for the Department of Health and Human Services, also blasted Hims’ knockoff pill, saying in a Feb. 7 X post that he has referred the matter “to the Department of Justice for investigation.”

Novo has also sued Hims for allegedly infringing on key patents protecting semaglutide. John Kuckelman, the pharma’s general counsel, said that the company could seek trebled damages that could reach “hundreds of millions” of dollars.

Why working out may not help you lose weight

According to conventional wisdom, a great way to lose weight is to do some exercise. While being active is beneficial in many ways for our health, it may not be very helpful if you want to shed a few inches off your waistline. And now, a new study published in Current Biology offers an explanation for why.

For decades, scientists have used a simple mathematical formula to calculate how much energy we use, which is essentially: Total Burn = Living Cost + Exercise. This is known as the Additive Model, and it means that every calorie you burn during a workout is simply added to the calories you use just to stay alive.

So, for example, if you burn 2,000 calories a day during your normal activities and then go for a run and burn 400 calories, you’ll burn 2,400 calories in a day according to the formula. The thought has been that this extra burn could lead to weight loss.

However, in recent years, another model has emerged called the Constrained Model. It says that our bodies have a limit on how much energy they spend. So if we burn more calories through exercise, the body reduces internal tasks, such as cell repair, to keep total energy expenditure within a narrow, predictable range. It means that the extra calories you thought you were burning at the gym are partially offset.

Comparing the models

Two researchers from Duke University in the U.S., Herman Pontzer and Eric T. Trexler, decided to compare these two ideas to see which one is supported by the data.

They analyzed 14 different studies involving 450 people who participated in exercise programs, as well as several animal studies. By comparing the energy these subjects were expected to burn with the energy they actually burned, the scientists calculated how much the body was compensating. They also compared data from different populations.

Their results suggested that the Additive Model often overestimates how much total daily energy expenditure rises with exercise. Instead, they found that as people and animals become more active, they may compensate by reducing energy spent on other processes or activities.

Realities of burning calories

On average, about 72% of the calories burned during exercise are added to the total daily burn. The remaining 28% may be offset through compensation. However, this is partial. Exercise still increases total energy use, but less than a simple additive calculation would predict. The researchers also noted that the 28% figure is an average and varies widely between individuals.

“Humans and other animals respond to increased physical activity by reducing energy expenditure on other tasks, supporting a constrained model of energy expenditure,” commented the researchers in their paper.

These findings may explain why exercise alone often leads to less weight loss than expected, and why diet plays such a key role.

Lucid dreaming could be used for mental health therapy, new study says

Lucid dreaming (LD) is one of the most fascinating parts of human consciousness, where you realize you are actually dreaming while you’re still asleep and, in some situations, can decide what happens next. There is a growing interest in lucid dreaming among scientists, but research is often scattered across different fields and long-term evidence of how it affects our health is lacking. So, a group of researchers conducted a massive review of existing studies to pull all the evidence together and discovered that this state of mind could help treat mental health issues like chronic nightmares and post-traumatic stress disorder (PTSD).

Understanding lucid dreaming

The team analyzed 38 peer-reviewed studies involving both healthy adults and those with conditions such as PTSD or Parkinson’s disease. They included only research that demonstrated lucid dreaming with objective data, such as specific eye-movement signals or brainwave patterns measured by an EEG (electroencephalogram).

Their review is published in the journal Annals of Medicine & Surgery.

When people enter a lucid dream, certain areas of the brain, like the prefrontal cortex (PFC), become more active. This region is associated with several key functions, including planning and decision-making, impulse control, working memory, and focus. During regular dreaming, it is usually much less active.

Some of the studies reviewed by the team also show increased gamma-band activity (around 40 Hz) in the frontal regions. These fast brainwaves are linked to higher-level thinking and help dreamers realize they are dreaming.

This awareness gives them a sense of control, which the researchers believe means that lucid dreaming could be used as a treatment for nightmares and PTSD.

Healing through dream control

For example, the researchers suggest that because lucid dreamers can confront and change the content of their dreams, treatments could be designed to help those with PTSD break the cycle of reliving traumatic memories. In other words, change or reframe a scary dream into a harmless one.

“Although evidence remains preliminary, LD shows promise as a therapeutic remedy for PTSD and anxiety symptoms, including a reduction in nightmares,” wrote the researchers in their paper. “It combines neuroscience and self-agency, highlighting the need for more funding and public awareness campaigns to harness its scientific and clinical prospects.”

While the study authors caution that their findings are still in the early stages, they believe future studies could explore using wearable technology to help people induce lucid dreaming on their own at home, away from a clinical setting.

Force-induced inter-protofilament gaps can pave the way for life in microtubule research

Constructed with tubulin heterodimers connected into a hollow cylinder, the microtubule, an essential component of the cytoskeleton, plays a vital role in various intracellular processes. In a recent study, a cross-disciplinary research team led by Professor Yuan Lin from the Department of Mechanical Engineering in the Faculty of Engineering, and Professor Jeff Ti from the School of Biomedical Sciences in the Li Ka Shing Faculty of Medicine at the University of Hong Kong (HKU), has revealed how the biological function of microtubules is achieved through mechanical regulation at the tubulin level.

Microtubules are hollow, cylindrical filamentous polymers of tubulins that function as force-bearing scaffolds or cargo-transport tracks in cells. To execute their biological functions, microtubules need to interact with groups of proteins—some binding to the microtubule’s exterior and others to its lumen. While the microtubule exterior is readily accessible to proteins, how luminal binding proteins gain access to the confined inner surface of microtubules remains a mystery. Specifically, the molecular mechanism by which the microtubule lattice determines the luminal accessibility has been elusive.

Combining single-molecule fluorescence microscopy-based assays with direct mechanical characterization by force microscopy, Professor Ti’s team, for the first time, revealed that tubulin isotypes (i.e., different variants of the tubulin protein) serve as the force-sensing element that regulates the accessibility of microtubule lumen for enzymes to interact with the substrates on the inner surface of the lattice. The research findings have been published in Nature Physics, titled “Tubulin isotypes of C. elegans harness the mechanosensitivity of the lattice for microtubule luminal accessibility.”

To elucidate the mechanistic insight into the roles of tubulin isotypes in regulating luminal accessibility, Professor Lin’s team developed a 3D computational model of the microtubule. Simulations revealed that the relatively weak lateral interaction of specific tubulin isotypes enables the reversible formation of inter-filament gaps when compressed. Experimentally validated, these transient gaps are large enough to allow entry of luminal binding proteins.

Together, these findings reveal a fundamental mechanism by which tubulin isotypes influence the strength of inter-protofilament lateral interactions, thereby governing luminal accessibility through reversible protofilament separation (i.e., lattice breathing). This demonstrates that the mechano-plasticity of microtubules can be regulated by their constituent tubulin isotypes, enabling distinct responses to thermally- or stress-induced mechanical deformation.

“In addition to significantly advancing our understanding of the phenomenon of mechano-transduction of cells, findings from this study could also provide critical insights for the development of novel active biomaterials in the future,” said Professor Lin and Professor Ti.

New tool cracks microbial defense codes for faster, precise bioengineering

Scientists at the Department of Energy’s Oak Ridge National Laboratory have developed software that reduces the time needed for a key task in the development of custom microbes from a week to just hours. The new tool cracks a key defense mechanism of microorganisms, expediting the creation of microbes with desired traits for the production of new biofuels and other valuable products for the bioeconomy.

The software, named MIJAMP, detects patterns of DNA sequences centered around methylation chemical markers, which function as gene on/off switches. These chemical modifications influence how microbes grow, defend themselves against viruses, and prevent new genetic material from entering a cell.

Microbes add these methyl groups to their DNA to signal enzymes to bypass the DNA segments while attacking any foreign DNA that doesn’t have the markers. This defense mechanism, called a restriction-modification system, can create challenges when scientists try to introduce new genetic material into microbes to give them enhanced properties for biomanufacturing.

MIJAMP uses outputs from synthetic biology tools, including nanopore sequencing data that identifies DNA letter order, to identify which parts of the microbial genome are marked with methyl groups. The process works by reading long stretches of DNA and then using pattern recognition algorithms to detect where the methyl groups are located.

The software, described in the Journal of Industrial Microbiology and Biotechnology, predicts which regions of the DNA are likely to contain the methyl markers that protect the cell, so that scientists can use those same markers to bypass the cell’s defense system. MIJAMP is open-source software, available on ORNL’s Gitlab.

A key feature of MIJAMP is its inclusion of a “human-in-the-loop” validation and refinement process to review predictions, recognizing that biological data doesn’t always behave in perfect, predictable ways.

MIJAMP discovered methylated motifs in dozens of naturally isolated microbial strains and modified bacteria. By identifying the exact positions and patterns of DNA methylation, scientists can use the tool to mimic these natural patterns and modify microbial DNA in a way that will not trigger defense mechanisms.

“The greatest impact is expediting the domestication of non-model microbes for specific, efficient functions,” said project lead Bill Alexander in ORNL’s Synthetic Biology Group. “A task that might have taken a synthetic biologist a week to work on, starting with the genome and requiring high-performance computing resources, can now take just an hour on a laptop.”

The new tool builds on a method developed by ORNL and other scientists as part of the DOE Center for Bioenergy Innovation to trick non-model microbes into accepting foreign DNA to enhance desired traits.

MIJAMP is part of a growing body of computational and other tools developed at ORNL for bioeconomy research. The tools automate synthetic biology workflows and accelerate biotechnology innovations, enhancing the nation’s energy security, innovation culture and global competitiveness.

These tools include:

Adaptation of the SAGE gene editing tool to give scientists the ability to insert and test new DNA designs in a variety of microbes faster.

Integration of the latest in mass spectrometry capabilities and expertise to analyze the plant root environment and help engineer plant-microbe interactions;

A new CRISPR interference technique to customize microbial traits faster; and

AI and molecular dynamics simulation tools to predict and facilitate beneficial plant-microbe relationships, supporting the DOE Genesis Mission for AI-driven scientific discovery.